BioCentury | Nov 30, 2017
Clinical News

eXIthera reports Phase I data for thrombosis candidate

...reported data from a Phase I trial in 60 healthy volunteers showing that thrombosis candidate EP-7041...
...the American Heart Association Scientific Sessions in Anaheim, Calif. Volunteers received single doses of IV EP-7041...
...trials of EP-7041, a factor XIa inhibitor, in 2H18. eXIthera Pharmaceuticals Inc., Westborough, Mass. Product: EP-7041...
Items per page:
1 - 1 of 1